Joep Killestein

PROF.DR., (Principal Investigator)

If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2001 2019

Acid sphingomyelinase: No potential as a biomarker for multiple sclerosis

Leurs, C. E., Lopes Pinheiro, M. A., Wierts, L., den Hoedt, S., Mulder, M. T., Eijlers, A. J. C., Schoonheim, M. M., Balk, L. J., Uitdehaag, B. M. J., Killestein, J. & de Vries, H. E., 1 Feb 2019, In : Multiple Sclerosis and Related Disorders. 28, p. 44-49 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation

van Kempen, Z. L. E., van Rossum, J. A., Doesburg, D., Claessen, I., de Vries, A., ten Brinke, A., van Oosten, B. W., Rispens, T. & Killestein, J., 2019, In : Journal of Neurology. 266, 7, p. 1804-1805

Research output: Contribution to journalComment/Letter to the editorAcademic

Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring

Killestein, J. & Reder, A. T., 9 Apr 2019, In : Neurology. 92, 15, p. 696-697

Research output: Contribution to journalEditorialAcademicpeer-review

Emerging safety issues in alemtuzumab-treated MS patients

Killestein, J. & van Oosten, B., 1 Aug 2019, In : Multiple Sclerosis Journal. 25, 9, p. 1206-1208 3 p.

Research output: Contribution to journalEditorialAcademicpeer-review

Open Access